Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000884
Status:
COMPLETED
Last Update Posted:
2021-10-29
First Post:
1999-11-02
Brief Title:
A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HIV Infections |
Keywords:
| Name | View |
|---|---|
| HIV Preventive Vaccine | View |
| Vaccines Synthetic | View |
| Injections Intramuscular | View |
| HIV-1 | View |
| Immunity Cellular | View |
| AIDS Vaccines | View |
| HIV Seronegativity | View |
| Mucous Membrane | View |
| Antibodies Viral | View |
| Avipoxvirus | View |
| Genetic Vectors | View |
| HIV Envelope Protein gp120 | View |
| Immunity Mucosal | View |
| Rabies Vaccines | View |